Using the same antibody as described above, an average of 7.0-fold increase in the DYRK1B levels was observed in the liver biopsies of NASH patients versus controls by immunofluorescence (Figure 1, H and I). The gene discussed is DYRK1B; the disease is metabolic dysfunction-associated steatohepatitis.